Skip to content
Screener

Denali Therapeutics Inc. DNLI Q1 2026 earnings

Reported May 7, 2026 · Before market open

EPS-$0.69Beat by $0.04
Revenue estimate$2.6M
EPS estimate-$0.73

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$12.2M
EPS estimate-$0.37

Financials

Q1 2026

Income statement

See full
Operating income-$137.4M+5.6%
Net income-$128.4M+3.4%
EPS (diluted)-$0.69+11.5%

Balance sheet

See full
Cash & equivalents$390.7M+551%
Total debt$40.0M-22.3%
Total equity$926.1M-17.5%
Total assets$1.3B-0.4%

Cash flow

See full
Operating cash flow-$131.2M+0.2%
CapEx$2.5M-51.4%
Free cash flow-$133.7M+2.1%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$3.04B+54.2%
Enterprise value$2.69B+37.1%

Returns & leverage

See full
Return on equity-49.6%+34.2pp
Debt / equity0×0.0×
Current ratio9.3×-0.3×

Segments

By product

See full
Milestone Triggered$25.0M0.0%
Milestone Payment$2.5M0.0%
Option Fee Payment$2.5M+100%

FAQ

When did Denali Therapeutics Inc. report Q1 2026 earnings?
Denali Therapeutics Inc. (DNLI) reported Q1 2026 earnings on May 7, 2026 before market open.
What were Denali Therapeutics Inc.'s Q1 2026 revenue and EPS?
Denali Therapeutics Inc. reported eps of $-0.69 for Q1 2026.
Did Denali Therapeutics Inc. beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.73 by $0.04.
How did Denali Therapeutics Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 11.5% from $-0.78.
Where can I find Denali Therapeutics Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001714899-26-000062) and the 10-Q periodic report (0001714899-26-000064) directly on SEC EDGAR. The filing index links above go to sec.gov.